Search results
Results from the WOW.Com Content Network
Trump said during a rally in late October that he would let Kennedy “go wild” on healthcare in the country, and vaccine stocks like Moderna and Novavax have been heading lower since. Thursday ...
An hour before the market closed Thursday, as news reports of Trump’s choice began trickling out, Covid-19 vaccine maker Moderna dipped as much as 6%, and Pfizer fell almost 2%.
Avian flu detection spurred the stocks of vaccine-makers this week. Image source: Getty Images. Therefore, the government appears to be looking for ways to supplement its supply should the current ...
The company — which expects its 2023 revenus to be at least $6 billion — reported $1.8 billion in COVID-19 vaccine sales in the third quarter and $3.9 billion through Q3.
The vote by the U.S. Senate Finance Committee paves the way for the full Senate to vote to confirm him as secretary of the U.S. Department of Health and Human Services as soon as this week ...
Bank of America analysts lowered their price target on Moderna last week, from $110 to $90, partially citing uncertainty after Trump's election win, while Deutsche Bank analyst Emmanuel Papadakis ...
Novavax successfully developed a COVID-19 vaccine that is currently its only product on the market. The company has been working on two other candidates. One is an investigational influenza vaccine.
Stocks fell Thursday, with the Dow and S&P 500 adding to Wednesday’s losses as optimism over a COVID-19 vaccine moderated further. The virus situation worsened in the U.S., with new COVID-19 ...